Hai Yan

List of Publications by Year
in descending order

44 papers	8,748 citations	279487 23 h-index	301761 39 g-index
44 all docs	44 docs citations	44 times ranked	13819 citing authors

#	Article	IF	Citations
1	<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas. New England Journal of Medicine, 2009, 360, 765-773.	13.9	5,285
2	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	3.3	1,202
3	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	0.6	221
4	The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology, 2021, 18, 645-661.	12.5	155
5	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. European Journal of Cancer, 2015, 51, 969-976.	1.3	150
6	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	9.4	148
7	The genome-wide mutational landscape of pituitary adenomas. Cell Research, 2016, 26, 1255-1259.	5.7	137
8	Mutant Metabolic Enzymes Are at the Origin of Gliomas. Cancer Research, 2009, 69, 9157-9159.	0.4	132
9	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	3.9	130
10	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6308-6312.	3.3	127
11	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	5.8	124
12	Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathologica, 2019, 137, 297-306.	3.9	109
13	Identification of recurrent USP48 and BRAF mutations in Cushingâ€™s disease. Nature Communications, 2018, 9, 3171.	5.8	106
14	The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Human Pathology, 2015, 46, 1626-1632.	1.1	88
15	Germline Mutations in CDH23, Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary Adenomas. American Journal of Human Genetics, 2017, 100, 817-823.	2.6	57
16	Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. Journal of Pathology, 2016, 239, 72-83.	2.1	56
17	Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of <i>ATRX</i>-Mutant Cancers to WEE1 Inhibition. Cancer Research, 2020, 80, 510-523.	0.4	52
18	Allelic variations in gene expression. Current Opinion in Oncology, 2004, 16, 39-43.	1.1	50

#	Article	IF	Citations
19	The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications, 2020, 11, 3077.	5.8	50
20	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. Cancer Research, 2017, 77, 6097-6108.	0.4	46
21	A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. Radiotherapy and Oncology, 2019, 130, 172-179.	0.3	42
22	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research, 2017, 15, 507-520.	1.5	41
23	TERTpromoter mutations contribute toIDHmutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget, 2015, 6, 24871-24883.	0.8	34
24	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. Cancer Research, 2019, 79, 3383-3394.	0.4	30
25	A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis. Cell Reports, 2019, 28, 3199-3211.e5.	2.9	27
26	Sensitive and rapid detection of<i>TERT</i>promoter and<i>IDH</i>mutations in diffuse gliomas. Neuro-Oncology, 2019, 21, 440-450.	0.6	27
27	Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget, 2017, 8, 76644-76655.	0.8	27
28	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 694-699.	1.0	18
29	Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Medicinal Chemistry Letters, 2018, 9, 606-611.	1.3	17
30	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry, 2016, 119, 218-230.	2.6	13
31	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	11
32	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathologica, 2018, 135, 285-298.	3.9	10
33	Chromatin Accessibility Mapping Identifies Mediators of Basal Transcription and Retinoid-Induced Repression of OTX2 in Medulloblastoma. PLoS ONE, 2014, 9, e107156.	1.1	8
34	Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. Scientific Reports, 2018, 8, 12507.	1.6	5
35	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. Neuro-Oncology, 2019, 21, vi7-vi7.	0.6	5
36	Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome. Familial Cancer, 2019, 18, 261-265.	0.9	3

#	Article	IF	Citations
37	Improved grading of IDH-mutated astrocytic gliomas. Nature Reviews Neurology, 2018, 14, 383-384.	4.9	2
38	Digital karyotyping: a powerful tool for cancer gene discovery. , 2006, , .		1
39	IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA. Neuro-Oncology, 2019, 21, vi126-vi126.	0.6	1
40	Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities. Cancer Discovery, 2020, 10, 1629-1631.	7.7	1
41	GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi112-vi112.	0.6	0
42	TMOD-33. ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS. Neuro-Oncology, 2018, 20, vi275-vi275.	0.6	0
43	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi102-vi103.	0.6	0
44	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. Neuro-Oncology, 2019, 21, vi8-vi8.	0.6	0